^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    belapectin (GR-MD-02)

    i
    Other names: GR-MD-02, GR-MD02, GR MD 02
    Associations

    News

    Trials
    Company:
    Galectin Therap
    Drug class:
    Galectin-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    NAVIGATE: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (clinicaltrials.gov)
    P2/3, N=357, Terminated, Galectin Therapeutics Inc. | Trial completion date: Sep 2025 --> Apr 2025 | Active, not recruiting --> Terminated; Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.
    Trial completion date • Trial termination
    |
    belapectin (GR-MD-02)
    3ms
    Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation. (PubMed, Biochim Biophys Acta Rev Cancer)
    Several galectin inhibitors (e.g., GR-MD-02, GB1211, LYT-200) are under clinical evaluation. Early trials showing encouraging efficacy-toxicity profiles and some combinations received FDA Fast Track designations. This review summarizes mechanistic and clinical advances and highlights their translational implications for galectin-targeted combination therapies.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    LYT-200 • belapectin (GR-MD-02) • selvigaltin (GB1211)
    10ms
    NAVIGATE: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (clinicaltrials.gov)
    P2/3, N=357, Active, not recruiting, Galectin Therapeutics Inc. | Phase classification: P2b --> P2/3 | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
    Phase classification • Trial completion date • Trial primary completion date
    |
    belapectin (GR-MD-02)
    over2years
    GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P2, N=0, Withdrawn, Providence Health & Services | N=92 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • LGALS3 (Galectin 3) • FAS (Fas cell surface death receptor) • FOXP3 (Forkhead Box P3) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)
    over2years
    GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P1, N=36, Completed, Providence Health & Services | Active, not recruiting --> Completed | N=22 --> 36 | Trial completion date: May 2025 --> Oct 2022
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)
    almost3years
    GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P2, N=92, Suspended, Providence Health & Services | Trial completion date: Mar 2031 --> Jul 2031 | Trial primary completion date: Mar 2027 --> Jul 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • LGALS3 (Galectin 3) • FAS (Fas cell surface death receptor) • FOXP3 (Forkhead Box P3) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)
    3years
    GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P2, N=92, Suspended, Providence Health & Services | Trial completion date: Dec 2030 --> Mar 2031 | Trial primary completion date: Dec 2026 --> Mar 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • LGALS3 (Galectin 3) • FAS (Fas cell surface death receptor) • FOXP3 (Forkhead Box P3)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)
    3years
    Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
    Plant-derived carbohydrates GM-CT-01 and GR-MD-02 were used to inhibit extracellular Galectin-1/-3 binding to BCP-ALL cells in co-culture with stromal cells. Treatment with these compounds attenuated migration of the BCP-ALL cells to stromal cells and sensitized human BCP-ALL cells to vincristine and the targeted tyrosine kinase inhibitor nilotinib...Taken together, our results indicate a complicated joint contribution of Galectin-1 and Galectin-3 to BCP-ALL survival, with different roles for endogenous and stromal produced Galectins. These data indicate it will be important to efficiently block both extracellular and intracellular Galectin-1 and Galectin-3 with the goal of reducing BCP-ALL persistence in the protective bone marrow niche during chemotherapy.
    Journal
    |
    LGALS1 (Galectin 1) • LGALS3 (Galectin 3) • ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1)
    |
    nilotinib • vincristine • Davanat (galactomannan) • belapectin (GR-MD-02)
    over3years
    GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P2, N=92, Suspended, Providence Health & Services | Trial completion date: Aug 2030 --> Dec 2030 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • LGALS3 (Galectin 3) • FAS (Fas cell surface death receptor) • FOXP3 (Forkhead Box P3)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)
    over3years
    GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Providence Health & Services | Trial primary completion date: May 2022 --> May 2023
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)
    almost4years
    GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P2, N=92, Suspended, Providence Health & Services | Initiation date: Jan 2022 --> Jul 2022
    Trial initiation date
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • LGALS3 (Galectin 3) • FAS (Fas cell surface death receptor) • FOXP3 (Forkhead Box P3)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)
    4years
    GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Providence Health & Services | Trial completion date: Oct 2021 --> May 2025 | Trial primary completion date: Oct 2021 --> May 2022
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02)